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Background: Up to 30% of patients with pancreatic cancer and more than 50% of patients with gastric cancer
already have incurable disease, with distressing symptoms of gastric outlet obstruction at the time of presentation
which require effective palliation. We decided to test the clinical outcomes of endoscopic stent placement in
malignant gastric outlet obstruction.
Methods: In a retrospective single institution-based study, the charts of patients who had self-expandable metal
stents placed to alleviate malignant gastric outlet obstruction were reviewed. Charts were reviewed to assess
improvement in oral intake according to the Gastric Outlet Obstruction Scoring System (GOOSS), and in order to
also evaluate technical success and complications of the procedure.
Results: 69 patients with successful stent placement were retrospectively evaluated. Within 7 and 28 days after
stent placement respectively, 85.5% and 80% benefited from stent insertion, with an increase in the GOOSS score
of > 1. Resumption of soft or low residue diet (GOOSS 2-3) was achieved in 53.6% at day 7 and in 62% of patients
at day 28, respectively. Of the patients achieving a GOOSS score of 2-3, 17.3% remained on a soft or low residue
diet at 24 weeks or at last follow up, while 46% died. Stent related adverse events occurred in 10 patients (14%),
including stent blockade in 7 and stent migration in 3 patients.
Conclusion: Endoscopic enteral stenting promptly increases oral intake in the majority of patients with malignant
gastric outlet obstruction and is a safe procedure with a low rate of serious complications.
Keywords: SEMS (self-expandable metal stents), Gastric outlet obstruction, GOOSS (gastric outlet obstruction
scoring system)Background
Malignant gastric outlet obstruction occurs in advanced
gastric, duodenal and pancreatobiliary malignancies. It
leads to intolerance of oral intake by causing vomiting,
resulting in weight loss and impaired quality of life. Recur-
rent vomiting also puts patients at risk of aspiration pneu-
monia [1-3]. Advances in chemotherapeutic agents have
improved survival in many of the malignancies cited above
[4]. A number of the newer anti-cancer agents used for
treating advanced gastric and pancreato-biliary cancers
are oral, such as capecitabine and erlotinib, so maintaining* Correspondence: halaqmc@yahoo.com
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distribution, and reproduction in any mediumoral intake is also helpful in providing treatment for many
of these tumors [5-11].
Traditionally, the standard treatment of malignant gastric
outlet obstruction has been surgical gastro-jejunostomy.
The advent of endoscopically-placed self-expandable me-
tallic stents has now widely changed practice, both in the
palliative setting in advanced malignancies with gastric out-
let obstruction as well as in the curative setting, where it is
important to relieve gastric outlet obstruction so as to
maintain nutrition during neo-adjuvant chemotherapy
[12,13]. In patients with limited life expectancy, metallic
stent insertion serves as an excellent palliative measure for
several reasons. It can be carried out as an outpatient pro-
cedure, is cheap compared to surgery, has high clinical
success rates, has low incidence of delayed gastricentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of oral feeding when compared with surgical gastro-
jejunostomy [14-17].
The aim of this study was to retrospectively analyze the
data of our hospital patients to determine the outcome of
stent placement at our institution. The main emphasis of
the study was to assess technical success rates and com-
plications of the procedure, as well as to evaluate im-
provement in oral intake after stent placement. This was
evaluated by assessing oral intake using the four-point
Gastric Outlet Obstruction Scoring System (GOOSS) by
retrospective data collection. Any procedure-related ad-
verse events were also studied to assess the safety of the
procedure.Methods
Patients
This retrospective study was conducted at Shaukat
Khanum Memorial Cancer Hospital & Research Centre,
Lahore, Pakistan, in accordance with the principles of
the Helsinki Declaration and after obtaining approval
from the Shaukat Khanum Memorial Cancer Hospital &
Research Centre Institutional Review Board. The data of
69 consecutive patients (37 males, age range 23-81 years;
mean 52.8 years) who had documented gastric outlet ob-
struction and who underwent endoscopic stenting from
August 2008 till January 2012 was reviewed retros-
pectively. All patients had symptomatic gastric outlet
obstruction that was characterized by vomiting and re-
duced oral intake, and confirmed at endoscopy or radio-
logically. Endoscopic pyloric stenting was the primary
treatment option to treat gastric outlet obstruction, in
accordance with decisions made in multidisciplinary
meetings. Palliative gastro-jejunostomy was reserved as a
second line measure in the event of failure of endoscopic
stenting or for stent blockade not amenable to endoscopic
re-stenting. Mildly symptomatic patients, in whom an
adult endoscope could be passed through the pylorus with
ease, were not stented.Procedure of stent placement
Initial upper GI endoscopy was performed to assess the
nature and site of obstruction. A biliary catheter and a
floppy guide-wire were used to negotiate the stricture
and contrast was injected under fluoroscopic control to
assess the length and extent of the stricture. The stent
delivery assembly was passed through the working chan-
nel of a therapeutic gastroscope, over the guide-wire,
and deployed under direct vision, with adjunct fluoro-
scopic control, in a standard manner. Patients usually
resumed oral intake of liquids within 6 hours of stent place-
ment. Diet was gradually advanced to a liquid/pureed diet
over 24 hours, and to a soft diet thereafter, as tolerated.Definitions
The outcome of SEMS placement was evaluated accor-
ding to the following parameters (1) technical success, (2)
clinical success, (3) complications. Technical success was
defined as correct placement of a stent in an appropriate
position, as confirmed by fluoroscopy. Symptoms consist-
ent with gastric outlet obstruction were defined as nausea,
vomiting and early satiety. The four point Gastric Outlet
Obstruction Scoring System (GOOSS) was retrospectively
used to assess the utility of stent insertion in relieving
obstruction : (0) no oral intake; (1) exclusively liquid diet;
(2) soft solids only; (3) low residue or full diet. We calcu-
lated the GOOSS score retrospectively for all patients, at
7 days, 28 days and 24 weeks after stent placement. Clin-
ical success was defined as improvement in the GOOSS
score after stenting.
Primary stent failure was defined as failure to resume
any oral intake after stent placement. Complications
were classed as either procedure-related, if they occurred
during endoscopy, or device-related if they occurred
later, and included stent blockade, migration, cholangitis,
duodenal perforation and intestinal hemorrhage.
Follow up
The patient’s charts were reviewed retrospectively to assess
clinical outcome and complications. Data was obtained
from the hospital records including inpatient admission
notes, clinic and emergency room visit notes, endoscopy re-
ports, radiology reports and from patients or their families
by telephonic enquiry. A follow up endoscopy or barium
study was performed to evaluate stent malfunction only in
patients with recurrent symptoms suggestive of obstruction.
Statistical analysis
The degree of oral intake before and after stent place-
ment was analyzed by SPSS version 19.
Results
Patient characteristics
77 stent insertion procedures were attempted in 69 patients
(37 males, age range 23-81 years; mean 52.8 years). 7 proce-
dures were performed in patients with a blocked stent. 5 of
these 7 patients had a successful stent insertion through a
previously inserted stent to treat stent blockade from tumor
ingrowth or overgrowth. One patient needed re-stenting to
manage stent migration. 44 patients had gastric carcinoma,
11 had pancreatic and periampullary tumors, 5 had carcin-
oma of the gall bladder and 3 had ovarian cancer while there
were 2 patients with diffuse large B cell lymphoma and one
patient each with duodenal, breast and rectal cancers, and
one patient with a retroperitoneal liposarcoma. The site of
obstruction was antro-pylorus in 45, duodenum in 20,
pylorus and duodenum in 3 and at the site of a previous
gastrojejunostomy in 1 patient.
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The technical success rate was 97%. At baseline, 68% of
patients had a GOOSS score of 0, while 30.4% had a score
of 1 (Table 1). By day 7, the GOOSS score had increased
> 1 in 85.5% patients, out of which the score had improved
to 2-3 in 53.6% (Table 2), a proportion that increased to
62% by day 28 (Table 3). However, by 24 weeks, 46% of
patients had died, 8.7% had a score of only 1, while 18.8%
had a score of 2–3 (Table 4). Four patients underwent sur-
gical resection of gastric tumours following stent insertion.
These were all patients who initially received neo-adjuvant
chemotherapy and in whom the tumour was judged to be
resectable at 24 weeks. 9 patients were lost to follow up
and could not be contacted by telephone.
A subgroup analysis was performed to assess the ef-
fects of chemotherapy on stent patency. Out of 56 pa-
tients who could be evaluated by day 28, 25 patients had
received chemotherapy. 14 of these 25 patients had a
GOOSS score of 0 at baseline and 11 had a score of 1.
At day 28, 6 patients had a GOOSS score of 1 and 19
had a score of 2-3. Out of 31 patients who did not re-
ceive chemotherapy, 25 patients had a GOOSS score of
0 at baseline and 6 had a score of 1. At day 28, 1 patient
had a GOOSS score of 0, 6 had a score of 1 while 24
had a score of 2-3 (p value = 0.139).
By 24 weeks, only 22 patients were evaluable. 32 had
died, 6 had undergone surgery and 9 were lost to follow-
up. Of these 22 patients, 11 had received chemotherapy
and a similar number had not. Of the 11 patients who re-
ceived chemotherapy, the baseline GOOSS score was 0 in
6 patients and 1 in 5 patients. By 24 weeks, the scores
were 0 in 1 patient, 1 in 1 patient and 2-3 in nine patients.
Of the 11 patients who did not receive chemotherapy,
baseline GOOSS scores were 0 in 8 patients and 1 in 3
patients. At 24 weeks, these were 0 in 2 patients, 1 in 5 pa-
tients and 2-3 in 4 patients (p value = 0.001).
Complications
Ten patients (14%) experienced device-related adverse
effects. Seven patients had stent blockade and three had
stent migration. Of the patients who had stent blockade,
this occurred within 28 days of insertion in one patient,
between one and six months in three patients and
between eight to twelve months post-stenting in three.
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cessfully inserted through the previously placed stents in
five of these seven patients. The remaining two patients
underwent palliative gastro-jejunostomy. Three patients
had stent migration between 7-42 days post-stenting.
One patient required repositioning of the stent, in an-
other a new stent was inserted while the third patient
was managed conservatively and allowed home without
further intervention in view of his very short life-
expectancy at that time. No other serious adverse events
occurred.
Discussion
Malignant gastric outlet obstruction greatly impairs the
quality of life by causing nausea, vomiting, abdominal
distension, dehydration, electrolyte imbalance, starvation
and weight loss [1-3,18]. Up to 30% of patients with
pancreatic and more than 50% of patients with gastric
cancer already have incurable disease, with distressing
symptoms of gastric outlet obstruction at the time of
presentation, and require effective palliation. The princi-
pal objective of palliative treatment in this situation is
the resolution of obstructive symptoms and resumption
of oral intake [19-21].
Insertion of SEMS has emerged as a safe and effective
means of palliation, avoiding the added risks of anaes-
thesia and surgery. Trials and meta-analyses have shown
that SEMS placement is superior to surgical gastro-
enterostomy, as evidenced by earlier resumption of oral
intake and shorter hospital stay [12,13,22,23]. SEMS
placement can be offered as first-line treatment of gas-
tric outlet obstruction in most patients, or as a second-
line therapy where surgery or other oncologic treatments
have failed to provide relief [17].
The GOO scoring system was first introduced in 2002,
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is now widely used and a number of studies have been
carried out using this scale, in order to evaluate oral
intake before and after stent placement. A number of
these have shown a favourable outcome with SEMS
placement [18,24,25]. In our study, improvement in the
GOOSS score was one of the parameters studied. Within
7 days of stent placement, 85.5% of patients had attained
a GOOSS score increase of > 1, and 53.6% had an im-
provement in GOOSS score to 2-3, implying resumption
of a soft or low residue diet. Of the patients attaining an
initial GOOSS score increase of > 1 and an absolute
score of 2-3, respectively 80% and 62% maintained these
improvements for 28 days, despite progressive disease in
many patients.
Our findings are largely consistent with previous stud-
ies. In a European multicenter study, van Hooft et al.
carried out a retrospective data analysis of 62 patients in
whom WallFlex enteral stents were inserted. All 56
evaluable patients had resumed some form of oral intake
by the end of week 1, consisting of liquids in 7 patients,
soft food in 17 and a low residue or full diet in 32 pa-
tients [26]. In a retrospective study of 95 patients with
gastric cancer, Cho et al. reported a technical success
rate of 98% for stent placement, and a clinical success
rate, defined as improvement in oral intake and ob-
structive symptoms 1-3 days after stent placement, of
87%. The GOOSS score was used to assess improvement
in oral intake. Recurrent symptoms of obstruction were
observed in 25/81 cases (30.8%), due to tumor ingrowth
in 23 and overgrowth in 2 patients. Mean survival was
129 days. Serious complications occurred in two patients
and were bowel perforation in one patient and aspiration
pneumonia in another [27].
In the prospective DUOFLEX study, the efficacy and
safety of the Wallflex stent in gastric outlet obstruction
was evaluated in 51 patients. Technical success was
achieved in 98% and clinical success was seen in 84% of
patients respectively, with 307 days of median stent pa-
tency (75% functional at 135 days and 25% at 470 days)
and median survival of 62 days (75% alive at 35 days and
25% at 156 days). This large difference between median
stent patency and median survival suggests that enteral
stenting adequately relieved GOO in the majority of
patients until death. 7 patients had stent dysfunction;migration in 1 and tumor ingrowth or overgrowth in 6.
The GOOSS score improved significantly (p < 0.001) and
the World Health Organization performance score also
improved, when the pre-stenting score was compared
with the mean score till death (p = 0.002). However, the
global quality of life did not improve, and the body mass
index decreased over time (p < .001), suggesting that in
palliation of patients with advanced cancer causing
GOO, attempts should be made not only to improve the
passage of food, but to also consider other factors that
might impair the quality of life including pain and psy-
chological factors [28].
In another prospective study of 37 patients performed
at three referral hospitals in Japan, the technical success
rate was reported as 97% and the clinical success rate
was 94.4%. However, the complication rate was relatively
high at 16.2%, with two cases of primary stent dysfunc-
tion, 1 perforation, 1 gastrointestinal bleed, 1 blocked
stent and one case of biliary stent dysfunction. The
follow-up period was also relatively short, with a median
follow-up period of 68 days [29]. In a retrospective Ko-
rean study of 82 patients, Morikawa et al. reported a
technical success rate of 93.9%, with mean GOOSS score
improving from 0.56 before stenting to 1.92 (p < 0.001)
after stenting. Complications were seen in 12 (14.6%) pa-
tients, with 10/12 developing stent blockade due to
tumor ingrowth and one patient each with stent migra-
tion and perforation. Median survival post stenting was
52 days (range 6-445 days) [30].
In a larger prospective study of 213 patients, the role
of chemotherapy in maintaining stent patency was also
studied. Technical and clinical success rates were com-
parable with other studies, at 94% each. The mean and
median stent patency periods were 324 and 270 days, re-
spectively. The mean and median survival recorded were
159 (CI 116-203) and 99 (CI 78-121) days, respectively.
Maintenance of stent patency was significantly higher in
those who received chemotherapy after SEMS insertion
(p < 0.001), although stent migration rates were also
increased [31]. In another study of SEMS placement in
patients with biliary tract malignancy causing duodenal
obstruction, stent placement was successful in all 17
patients and all patients were able to tolerate soft or
solid food by 4 weeks. There were no procedure-related
deaths [32].
In comparing our outcomes with the literature, we
found that our technical and clinical success rates were
comparable to most studies [26-28,30], although the study
by Kim et al. had better clinical outcomes in terms of
longer stent patency related to the effect of chemotherapy
[31]. Subgroup analysis of our patients who received
chemotherapy did not show a significant difference in
GOOSS score by day 28 post-stenting when compared
with those who had not received chemotherapy. However,
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and less obstructive symptoms by 24 weeks post stenting
was seen (82% with a score of 2-3 in the chemotherapy
group vs 36% with a score of 2-3 in those who did not
receive chemotherapy). Clearly, however, the number of
patients was too small to establish any clinical significance.
Although serious complications associated with SEMS
insertion have been reported, such as gastrointestinal
hemorrhage, sepsis, cholangitis, bowel perforation and as-
piration pneumonia [18,27,29,30], the incidence of such
complications is low, with most complications being non-
fatal [27-30,32]. In our study, there were no incidents of
stent-related bowel perforation, aspiration pneumonia,
cholangitis or sepsis. The median survival time in malig-
nancies with gastric outlet obstruction is generally short,
ranging from 49-99 days. In our study, 46% of patients
had died by 24 weeks, but, as already discussed, it has
been shown that the lower morbidity and earlier resump-
tion of oral intake in these patients does lead to an im-
proved quality of life when compared with those treated
surgically.
Conclusions
From our experience, it seems clear that endoscopic stent
placement ought to be considered a first-line measure to
relieve gastric outlet obstruction in this population with a
limited life expectancy. Further controlled studies are re-
quired to assess the role of chemotherapy, radiotherapy
and the effect of the primary malignancy on stent patency.
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